BRAF V600E mutation are predictive of response to BRAF inhibitors in melanoma and have been reported to predict response in other BRAF-positive malignancies such as hairy cell leukemia [68], histiocytosis, [69] and thyroid cancer [70,71], but not in colorectal cancer [72]. Here, BRAF is linked to thyroid gland carcinoma.